

The 10th Annual Pulmonary Hypertension & the 5th Pulmonary Hypertension of the Young Joint Conference of the Saudi Association for Pulmonary Hypertension

The Westin Dubai Al Habtoor City, Dubai, UAE

SCIENTIFIC PROGRAM



www.saph2017.com





Scientific Program: Registration

Day 1: Thursday, 2 February 2017 | Time: 15:30 –16:15

15:30 -16:15	REGISTRATION	
16:15 - 16:30	OPENING CEREMONY	
	WELCOME NOTE	
	Abdulla Aldalaan President Elect 2017, SAPH	
	Saleh Aldammas Chair, SAPH 2017	





Scientific Program : Session I

Day 1: Thursday, 2 February 2017 | Time: 16:30 - 18:00

	SESSION - I		
TITLE	PULMONARY HYPERTENSION: UNDERSTANDING THE BASICS		
OBJECTIVES	This is a special session designed for a better understanding of the basic differences between the different groups of pulmonary hypertension.		
CHAIRPERSONS	Paul Corris UK Saleh Aldammas		
TIME	ТОРІС	SPEAKER	
16:30 - 16:50	PAH: why it is different? Understanding the core of the problem		
16:50 - 17:10	After 20 years of medical therapy, what have we accomplished?		
17:10 - 17:30	What is in the horizon for PAH?	Sanjay Mehta Canada	
17:30 - 17:50	PH in lung disease; updates in management	Paul Corris	
17:50 - 18:00	GENERAL DISCUSSION		
18:20 - 18:45	COFFEE BREAK		





Scientific Program: Session II

Day 1: Thursday, 2 February 2017 | Time: 18:00 – 19:30

SESSION - II			
TITLE	PULMONARY EMBOLISM & VENOUS THROMBOEMBOLISM		
OBJECTIVES	This is a special session designed to better understand the new updates in the management of pulmonary embolism.		
CHAIRPERSONS	M. Ali Azem KSA Manal Alhazmi		
TIME	ТОРІС	SPEAKER	
18:00 - 18:20	ACCP VTE Guidelines: the new updates Sponsored by: Bayer	Mohammed Zeitouni KSA	
18:20 - 18:40	The clot journey from acute PE to CTEPH	Abdulla Aldalaan KSA	
18:40 - 19:00	Acute pulmonary hypertension in PE, should we target with therapy?	Majdy Idrees KSA	
19:00 - 19:20	The new oral anticoagulants; differences and similarities! Hussam Sakkijha Sponsored by: Bayer		
19:20 - 19:30	GENERAL DISCUSSION		







Scientific Program: Session III

Day 1: Thursday, 2 February 2017 | Time: 19:30 - 20:30

SESSION - III			
TITLE	SAUDI RESEARCH INITIATIVES & ABSTRACT PRESENTATIONS		
OBJECTIVES	This is a special session designed to present the work done locally in the field of PH		
CHAIRPERSONS	Hatem Qutb KSA Abdulla Aldhalaan KSA		
TIME	ТОРІС	SPEAKER	
19:30 - 19:50	PAH is Saudi scleroderma patients	Hadil Alotair KSA	
19:50 - 20:00	Aerosolized B-type natriuretic peptide for the treatment of TB-associated PH	Dorian Bevec Germany	
20:00 - 20:10	ABSTRACT 3		
20:10 - 20:20	ABSTRACT 4		
20:20 - 20:30	GENERAL DISCUSSION		
20:30 - 22:00	DINNER		





Scientific Program: Session IV

Day 2: Friday, 3 February 2017 | Time: 09:30 - 11:00

SESSION - IV			
TITLE	PH IN THE YOUNG		
OBJECTIVES	This session addresses the emerging conditions that are specific to young patients. It also concentrates on potential differences that applied to pediatric population.		
CHAIRPERSONS	Maha Aldabbagh KSA Hanaa Banjar KSA		
TIME	ΤΟΡΙϹ	SPEAKER	
09:30 - 09:50	The TOPP Registry	Rolf Berger Netherland	
09:50 - 10:10	Monitoring disease progression in pediatric PH	Damien Bonnet France	
10:10 - 10:30	PH in ILD in children; a difficult problem	Rolf Berger Netherland	
10:30 - 10:50	PH in Bronchopulmonary dysplasia	Damien Bonnet France	
10:50 - 11:00	GENERAL DISCUSSION		
11:00 - 11:20	COFFEE BREAK		
		Tribunity of the second	





Scientific Program: Session V

Day 2: Friday, 3 February 2017 | Time: 11:20 - 12:30

HOT TOPICS IN PH		
A very important session that focus on hot topics in different diseases presented with pulmonary hypertension		
Badr Al-Ghamdi KSA	Hadil Alotair KSA	
ΤΟΡΙϹ	SPEAKER	
Biologics of CTD-PAH	Sanjay Mehta Canada	
Cost effectiveness of combination therapy for PAH Research Cost effectiveness of combination therapy for PAH		
CTEPH: synopsis from the Canadian guidelines John Swiston Canada		
A quick look at PH group V diseases; the forgotten group		
GENERAL DISCUSSION		
GROUP PHOTO, LUNCH		
	pulmonary hypertension Fact AI-Ghamdi TOPIC TOPIC Biologics of CTD-PAH Cost effectiveness of combination therapy for PAH CTEPH: synopsis from the Canadian guidelines A quick look at PH group V diseases; the forgotten group GENERAL DISCUSSION GROUP PHOTO, LUNCH	





Scientific Program: Session VI

Day 2: Friday, 3 February 2017 | Time: 14:30 - 15:45

SESSION - VI			
TITLE	ΜΙΝΙ SYMPOSIA		
OBJECTIVES	In these symposia, you will have the chance to choose your own topics and to go deep in discussion with expert faculties.		
SECTION	HEMODYNAMICS IN PAH	DIAGNOSING ALGORITHM	PAH TREATMENT
CHAIRPERSONS	Khalid Najashi KSA	Waleed Alhabib KSA	Sarfraz Saleemi KSA
TIME	TOPIC & SPEAKER	TOPIC & SPEAKER	TOPIC & SPEAKER
14:30 - 14:50	Pitfalls in RHC Hani Sabbour UAE	The role of echo (pediatric) Abdelmajeed Alotay KSA	Riociguat: is it another PDE5i-like drug? Marius Hoeper UAE
14:50 - 15:10	Prognostic hemodynamics Tarek Kashour KSA	The role of echo Firas Bader KSA	Macitentan: is it just another ERAs? Jean-Luc Vachiéry Belgium
15:10 - 15:30	RHC in pediatric patients Omar Tamimi KSA	The role of radiology Nasser Alamri KSA	Selexipag: is it just another oral PC? Luke Howard UK
15:30 - 15:45	Q & A	Q & A	Q & A
19:30 - 22:00	GALA DINNER		





Scientific Program: Session VII

Day 3: Saturday, 4 February 2017 | Time: 09:30 - 10:15

		SESSION - VII	
TITLE	MEET THE EXPERTS		
OBJECTIVES	In this session you will have the chance to choose your own topics and to go deep in discussion with expert faculties		
GROUP	Group 1 - PHA Canada	Group 2 - SAPH - PH in the Young	Group 3 - PHA USA & Europe
	Parenteral prostacyclin?	PH in young patients	How to establish PH patients' group?
TIME	TOPIC & SPEAKER	TOPIC & SPEAKER	TOPIC & SPEAKER
09:30 - 10:30	Prostanoids? Where do they fit in the management of PH? Robert Levy CanadaCanadaCanadaCanadaCanadaCanadaCanadaCanadaCanadaCanadaCanadaCanadaCanadaCanadaCanada	Childhood PH at high altitude? A special consideration. M Omar Gala KSAImage: Consideration of the special consideration. M Omar Gala KSAImage: Consideration of the special consideration of the special of the special consideration of the special of the special of the special consideration of the special of	Understanding patients' needs Michael Gray USAImage: Strategic planning and patients' group? Juan Fuertes Spain
10:30 - 10:45	BREAK		





Scientific Program: Session VIII

Day 3: Saturday, 4 February 2017 | Time: 10:45 - 12:00

	SESSION - VI	11	
TITLE	CLINICAL CASES IN PH (CLINICAL – RADIOLOGICAL – PHYSIOLOGICAL CORRELATION)		
OBJECTIVES	In this session you will face challenging clinical cases and a full discussion about such clinical scenarios		
CHAIRPERSONS	Mohamed Zeitouni KSA	Maan Fetaih KSA	
TIME	ТОРІС	SPEAKER	
10:45 - 11:10	CASE 1 Sharifa Makhdari KSA 10:45 - 10:55	Tarek Kashour (Moderator) KSA 10:55 – 11:10	
11:10 - 11:35	CASE 2 Bader Alghamdi KSA 11:10 - 11:20	Abdelghafour Gari (Moderator) KSA 11:20 - 11:35	
11:35 - 12:00	CASE3 Samar Farha UAE 11:35 - 11:45	Husam Sakkijha (Moderator) KSA 11:45 - 12:00	
12:00	CLOSING & GROUP DEPARTURE		